Equities research analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to post ($0.78) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.89). The firm is scheduled to report its next quarterly earnings report on Thursday, March 14th.
According to Zacks, analysts expect that Crispr Therapeutics will report full year earnings of ($3.26) per share for the current financial year, with EPS estimates ranging from ($3.33) to ($3.08). For the next financial year, analysts anticipate that the firm will report earnings of ($3.47) per share, with EPS estimates ranging from ($4.05) to ($1.86). Zacks’ EPS averages are an average based on a survey of research analysts that cover Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.33). Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The firm had revenue of $0.56 million for the quarter, compared to analyst estimates of $2.64 million. During the same quarter in the previous year, the company earned ($0.62) EPS. The company’s quarterly revenue was down 76.6% compared to the same quarter last year.
NASDAQ CRSP traded up $1.25 on Wednesday, hitting $37.13. 670,784 shares of the stock traded hands, compared to its average volume of 882,965. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $73.90. The stock has a market capitalization of $1.86 billion, a P/E ratio of -21.71 and a beta of 3.48.
In other Crispr Therapeutics news, major shareholder Vertex Pharmaceuticals (Europe bought 22,742 shares of the stock in a transaction that occurred on Friday, December 21st. The shares were purchased at an average cost of $22.58 per share, for a total transaction of $513,514.36. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Rodger Novak sold 17,310 shares of the firm’s stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $35.09, for a total value of $607,407.90. Following the completion of the sale, the president now owns 1,130,697 shares in the company, valued at $39,676,157.73. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 153,682 shares of company stock worth $3,700,718. 37.70% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in Crispr Therapeutics by 26.5% during the 2nd quarter. Bank of America Corp DE now owns 9,407 shares of the company’s stock valued at $553,000 after purchasing an additional 1,972 shares in the last quarter. TRUE Private Wealth Advisors bought a new position in Crispr Therapeutics during the 3rd quarter valued at $122,000. Vanguard Group Inc. boosted its stake in Crispr Therapeutics by 6.6% during the 3rd quarter. Vanguard Group Inc. now owns 52,023 shares of the company’s stock valued at $2,307,000 after purchasing an additional 3,200 shares in the last quarter. Vanguard Group Inc boosted its stake in Crispr Therapeutics by 6.6% during the 3rd quarter. Vanguard Group Inc now owns 52,023 shares of the company’s stock valued at $2,307,000 after purchasing an additional 3,200 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Crispr Therapeutics by 11.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 34,618 shares of the company’s stock valued at $1,535,000 after purchasing an additional 3,514 shares in the last quarter. Hedge funds and other institutional investors own 43.83% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Read More: What is Cost of Capital?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.